Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (6842)	7/29/1998 8:52:00 PM
From: John Patterson	Read Replies (2) \| Respond to of 17367

Bluegreen, Not much input I could give there. I am a cardiac perfusionist, (specialist with heart-lung machines, oxygenators, artifical hearts, etc.). I work with a group of cardiac surgeons and if it were not for my cheer leading, they would have never heard of XOMA or BPI. I talked with our consult for infectious diseases and he was also clueless, however he was very intrigued with the concept. I've seen plenty of post-op infections over the last 25 years, and if you get behind the curve and the situation deteriorates to sepsis, you're in deep trouble. The inflammatory cascade causes a rapid downward spiraling that is extremely difficult to halt. Obviously a drug like Neuprex would be a literal lifesaver. It would represent a paradigm shift in the treatment of sepsis, right now the treatment is reactive, in other words you treat the symptoms as they manifest.